colored cancer cells

Visualizing the Future: Spatialomics Transforms Study of Gene Expression

Gene editing

Home » Emerging technologies » Gene editing

Synthego

Synthego Launches Eclipse Platform to Accelerate Research and Development of Next-generation Medicines

MENLO PARK, California — Synthego, the genome engineering company, today announced the launch of Eclipse™, a new high-throughput cell engineering platform designed to accelerate drug discovery and validation by...

mushroom

Inscripta Announces the First Commercial Shipment of Its Onyx™ Digital Genome Engineering Platform and Closes $150 Million in New Financing

eGenesis Expands Research Collaboration with Leading Academic Medical Center

Collaboration will now include in vivo testing of lead kidney xenotransplant program in addition to pancreatic islet xenotransplant program CAMBRIDGE, Mass., April 1, 2021 — eGenesis, a gene-editing and genome...

mushroom

Amfora Raises $6 Million with Investment from Leaps by Bayer and Spruce Capital Partners

mushroom

Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies

mushroom

Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

CRISPR Clinical Trials

CRISPR Clinical Trials: A 2021 Update

mushroom

eGenesis Announces $125 Million Series C Financing

mushroom

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs

mushroom

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement

mushroom

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease

Could Crispr Eradicate Acne?

mushroom

Editas Medicine Announces The FDA Has Cleared Initiation Of The EDIT-301 Clinical Trial

mushroom

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

mushroom

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares